[1] Bray F, Ferlay J, Soerjomataram I, et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in185 countries[J]. CA: Cancer J Clin, 2018, 68(6): 394-424.   doi: 10.3322/caac.21492
[2] 严浩, 何杨, 杨润峰, 等.  复发性卵巢癌的临床特点分析[J]. 中国医师杂志, 2015, 17(4): 487-490.   doi: 10.3760/cma.j.issn.1008-1372.2015.04.003
Yan H, He Y, Yang RF, et al.  Clinical features of patients with recurrent epithelial ovarian cancer[J]. J Chin Physician, 2015, 17(4): 487-490.   doi: 10.3760/cma.j.issn.1008-1372.2015.04.003
[3] Lee CK, Lord S, Grunewald T, et al.  Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial[J]. Gynecol Oncol, 2015, 136(1): 18-24.   doi: 10.1016/j.ygyno.2014.09.017
[4] 李敏, 李绪清, 颜士杰, 等.  18F-脱氧葡萄糖PET/CT联合CA125在诊断卵巢癌复发转移中的应用价值[J]. 重庆医科大学学报, 2017, 42(12): 1635-1638.   doi: 10.13406/j.cnki.cyxb.001417
Li M, Li XQ, Yan SJ, et al.  Value of 18F-fluorodeoxyglucose PET/CT combined with serum carbohydrate antigen 125 in detecting the recurrence and metastasis of postoperative ovarian cancer[J]. J Chongqing Med Univ, 2017, 42(12): 1635-1638.   doi: 10.13406/j.cnki.cyxb.001417
[5]

邵婷, 陈秀玮. 卵巢癌的病因假说及危险因素和流行病学研究进展[J/OL]. 中华临床医师杂志: 电子版, 2013, 7(19): 8894−8897[2020-08-27]. https://d.wanfangdata.com.cn/periodical/zhlcyszz201319081. DOI: 10.3877/cma.j.issn.1674-0785.2013.19.082.

Shao T, Chen XW. Etiological hypothesis, risk factors and epidemiological research progress of ovarian cancer[J/OL]. Chin J Clin (Electron Ed), 2013, 7(19): 8894−8897[2020-08-27]. https://d.wanfangdata.com.cn/periodical/zhlcyszz201319081. DOI: 10.3877/cma.j.issn.1674-0785.2013.19.082.
[6] Thrall MM, DeLoia JA, Gallion H, et al.  Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer[J]. Gynecol Oncol, 2007, 105(1): 17-22.   doi: 10.1016/j.ygyno.2006.10.060
[7] 徐晓伟, 周春英, 王俊霞, 等.  血清甲胎蛋白、人附睾蛋白4及糖类抗原125水平与卵巢癌相关性分析[J]. 临床合理用药杂志, 2015, 8(4): 162, 164-.   doi: 10.15887/j.cnki.13-1389/r.2015.04.098
Xu XW, Zhou CY, Wang JX, et al.  Correlation between serum alpha fetoprotein, human epididymal protein 4 and carbohydrate antigen 125 and ovarian cancer[J]. Chin J Clin Ration Drug Use, 2015, 8(4): 162, 164-.   doi: 10.15887/j.cnki.13-1389/r.2015.04.098
[8] 关鑫, 刁海丹.  HE4在卵巢癌术后复发中的预测价值研究[J]. 中国实用医药, 2016, 11(31): 61-62.   doi: 10.14163/j.cnki.11-5547/r.2016.31.035
Guan X, Diao HD.  Predictive value of HE4 in postoperative recurrence of ovarian cancer[J]. China Prac Med, 2016, 11(31): 61-62.   doi: 10.14163/j.cnki.11-5547/r.2016.31.035
[9] Anthony MP, Khong PL, Zhang JB.  Spectrum of 18F-FDG PET/CT appearances in peritoneal disease[J]. AJR Am J Roentgenol, 2009, 193(6): W523-W529.   doi: 10.2214/AJR.09.2936
[10] 卢淮武, 霍楚莹, 林仲秋.  《2019NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2019, 35(5): 536-546.   doi: 10.19538/j.fk2019050112
Lu HW, Huo CY, Lin ZQ.  Interpretation of 2019 NCCN clinical practice guidelines to ovariam cancer including fallopian cancer and primary peritoneal cancer (1st edition)[J]. Chin J Pract Gynecol Obstet, 2019, 35(5): 536-546.   doi: 10.19538/j.fk2019050112
[11] 卢淮武, 霍楚莹, 许妙纯, 等.  《2020NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2020, 36(4): 340-348.   doi: 10.19538/j.fk2020040113
Lu HW, Huo CY, Xu MC, et al.  Interpretation of "NCCN guidelines version 1.2020 ovarian cancer/fallopian tube cancer/primary peritoneal cancer"[J]. Chin J Pract Gynecol Obstet, 2020, 36(4): 340-348.   doi: 10.19538/j.fk2020040113
[12] 罗丹, 孔为民.  复发性卵巢癌治疗的研究进展[J]. 癌症进展, 2019, 17(17): 2003-2006.   doi: 10.11877/j.issn.1672-1535.2019.17.17.06
Luo D, Kong WM.  Research progress in the treatment of recurrent ovarian cancer[J]. Oncol Prog, 2019, 17(17): 2003-2006.   doi: 10.11877/j.issn.1672-1535.2019.17.17.06
[13] 唐梅, 林丽慧, 林元, 等.  血清人附睾蛋白4与CA125在上皮性卵巢癌中的表达及其与预后的关系[J]. 解放军医学院学报, 2018, 39(1): 24-27.   doi: 10.3969/j.issn.2095-5227.2018.01.007
Tang M, Lin LH, Lin Y, et al.  Expressions of serum human epididymis protein 4 and CA125 in patients with epithelial ovarian cancer and their relationships with prognosis[J]. Acad J Chin PLA Med Sch, 2018, 39(1): 24-27.   doi: 10.3969/j.issn.2095-5227.2018.01.007
[14] 马克奇, 王丰梅.  HE4、Kif2a在卵巢上皮性肿瘤中的表达与研究进展[J]. 临床医药文献电子杂志, 2019, 6(70): 194-.   doi: 10.16281/j.cnki.jocml.2019.70.173
Ma KQ, Wang FM.  Expression and research progress of HE4 and Kif2a in ovarian epithelial tumors[J]. Electron J Clin Med Lit, 2019, 6(70): 194-.   doi: 10.16281/j.cnki.jocml.2019.70.173
[15] 卢媛媛, 江飞云, 吴守乐.  人血清附睾蛋白与糖类抗原检测在卵巢癌诊断中的价值[J]. 华北理工大学学报(医学版), 2018, 20(3): 214-219.   doi: 10.19539/j.cnki.2095-2694.2018.03.010
Lu YY, Jiang FY, Wu SL.  Value of serum HE4 and CA125 single and combined detection in ovarian cancer diagnosis[J]. J North China Univ Sci Technol: Health Sci Ed, 2018, 20(3): 214-219.   doi: 10.19539/j.cnki.2095-2694.2018.03.010
[16] Castellucci P, Perrone AM, Picchio M, et al.  Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology[J]. Nucl Med Commun, 2007, 28(8): 589-595.   doi: 10.1097/MNM.0b013e3281afa256
[17] Gu P, Pan LL, Wu SQ, et al.  CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis[J]. Eur J Radiol, 2009, 71(1): 164-174.   doi: 10.1016/j.ejrad.2008.02.019
[18] Yuan Y, Gu ZX, Tao XF, et al.  Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis[J]. Eur J Radiol, 2012, 81(5): 1002-1006.   doi: 10.1016/j.ejrad.2011.01.112
[19] 智生芳, 毕伟, 黄晓红, 等.  18F-FDG PET/CT对卵巢癌患者术后复发、转移的诊断敏感性及准确性研究[J]. 中国CT和MRI杂志, 2016, 14(2): 100-102, 111.   doi: 10.3969/j.issn.1672-5131.2016.02.032
Zhi SF, Bi W, Huang XH, et al.  Study on the sensitivity and accuracy of PET/CT 18F-FDG in the diagnosis of postoperative recurrence and metastasis in patients with ovarian cancer[J]. Chin J CT MRI, 2016, 14(2): 100-102, 111.   doi: 10.3969/j.issn.1672-5131.2016.02.032
[20] 卢仁泉, 郭林, 沈烨红.  HE4在卵巢癌诊治中的临床应用评价[J]. 中国癌症杂志, 2010, 20(9): 680-685.   doi: 10.3969/j.issn.1007-3639.2010.09.008
Lu RQ, Guo L, Shen YH.  The value of human epididymis protein 4 in patients with ovarian cancer[J]. China Oncol, 2010, 20(9): 680-685.   doi: 10.3969/j.issn.1007-3639.2010.09.008
[21] Hebel CB, Behrendt FF, Heinzel A, et al.  Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer[J]. Eur J Radiol, 2014, 83(3): 463-467.   doi: 10.1016/j.ejrad.2013.12.006
[22] Fularz M, Adamiak P, Czepczyński R, et al.  Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level[J]. Nuklearmedizin, 2015, 54(4): 158-162.   doi: 10.3413/Nukmed-0709-14-11
[23] Sironi S, Messa C, Mangili G, et al.  Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings[J]. Radiology, 2004, 233(2): 433-440.   doi: 10.1148/radiol.2332031800